Ebola Treatment Market Size Analysis and Forecast (2019-2025) : Arbutus Biopharma, GlaxoSmithKline, Johnson & Johnson Services
QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.
Los Angeles, CA -- (SBWire) -- 05/28/2019 --Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash, muscular pain, etc. Ebola virus causes haemorrhagic fever which may lead to internal or external bleeding. The symptoms appear anywhere from 2 to 21 days after exposure to Ebola, though the average is 8 to 10 days. Diagnostic tests are now being done by ELISA (Antigen-capture enzyme-linked immunosorbent assay), Polymerase Chain Reaction, Virus Location, IgM Elisa and Immunohistochemistry testing. Few vaccines and medical treatments for Ebola are in pipeline and due to the absence of effective treatments, the pharmaceutical companies now have big opportunities in the market globally. As per WHO, several care rehydration methods are adopted with fluid injection orally and other treatments are also taken care of which improves the survival rate. Top drug companies such as Hemispherx Biopharma, Biochryst Pharmaceuticals, Nano Vircides, Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceuticals are among the key players in the global Ebola treatment market and are conducting trials on a set of experimental drugs.
The global Ebola treatment market growth is driven by the increasing incidence rates of Ebola viral infection and Ebola outbreaks. As per WHO, U.S. & U.K. governments, availability of different treatment procedures to treat Ebola is expected to drive the Ebola viral disease market growth during the forecast period. The Ebola treatment market also includes therapies for those who already have Ebola, and vaccines to prevent the deadly virus. Various drug companies and regulators in the U.S. are taking a two-pronged approach in finding a way to treat the virus. Approval of vaccines are taking a longer time but when vaccines undergo trials, adoption and availability could be a limiting factor for global Ebola treatment market growth.
Get PDF of this report template: https://www.qyresearch.com/sample-form/form/1119471/global-ebola-treatment-market
This report studies the Ebola Treatment market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Ebola Treatment in these regions, from 2014 to 2025, covering
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil etc.)
Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
Arbutus Biopharma
GlaxoSmithKline
Johnson & Johnson Services
Hemispherx Biopharma
BioCryst Pharmaceuticals
NanoViricides
NewLink Genetics
Chimerix
Sarepta Therapeutics
Mapp Biopharmaceutical
By the product type, the market is primarily split into
Vaccine (Under Trials)
Drugs (Under Trials)
By the end users/application, this report covers the following segments
Hospitals
Ambulatory Surgery Centres
Specialized Clinics
Army Camps (Veteran Facilities)
Get Customized Report in your Inbox within 24 hours @: https://www.qyresearch.com/customize-request/form/1119471/global-ebola-treatment-market
Benefits of Purchasing QY Research Report
- Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report
- Customer's Satisfaction: Our expert team will assist with all your research needs and customize the report
- Inimitable Expertise: Analysts will provide deep insights about the reports
- Assured Quality: We focus on the quality and accuracy of the report
About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.
Media Relations Contact
Rahul Singh
Director - Digital Marketing
QY Research, Inc.
1-626-295-2442
https://www.qyresearch.com/index/detail/1119471/global-ebola-treatment-market
View this press release online at: http://rwire.com/1225626